Phillip Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Phillip Tran has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Nghia Phu Nguyen
School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
6 shared publications - Mohammad Najm Dadam
Online Research Club, Nagasaki, Japan
2 shared publications - Nguyen Tien Huy
Institute of Research and Development Duy Tan University Da Nang Vietnam
2 shared publications - Abdelrahman Gad
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
1 shared publication - Ahmed M. Sayed
Affiliation Department of Chemistry, College of Science, Purdue University, West Lafayette, Indiana, United States of America
1 shared publication - Ai Cao My Bui
School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
1 shared publication
Latest Publications
- 21 September 2026
- Published by Springer Nature in Journal of General Internal Medicine
- p. 1-2
Making AI work for Equity in Primary Care
- 21 September 2026
- Published by Springer Nature in Journal of General Internal Medicine
- p. 1-2
Making AI work for Equity in Primary Care
- 9 April 2026
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 8 (1) , 113
Wellens Syndrome in the Modern Era: A Contemporary Review
- 9 April 2026
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 8 (1) , 113
Wellens Syndrome in the Modern Era: A Contemporary Review
- Open Access
- 27 March 2026
- Published by Elsevier in Mayo Clinic Proceedings: Digital Health
- Vol. 4 (2) , 100354
The Third Presence in the Clinic Room: How Artificial Intelligence Is Reshaping the Clinical Encounter
- 27 March 2026
- Published by Elsevier in Mayo Clinic Proceedings: Digital Health
- Vol. 4 (2) , 100354
Open AccessThe Third Presence in the Clinic Room: How Artificial Intelligence Is Reshaping the Clinical Encounter
- Open Access
- 29 January 2026
- Published by Wiley in MedComm – Future Medicine
- Vol. 5 (1)
Cardiotropic Gene Therapy for Heart Failure: Translational Lessons From AB‐1002
- 29 January 2026
- Published by Wiley in MedComm – Future Medicine
- Vol. 5 (1)
Open AccessCardiotropic Gene Therapy for Heart Failure: Translational Lessons From AB‐1002
- Open Access
- 9 January 2026
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1) , 29
Bridging the mentorship divide: how large language models could reshape medical workforce equity
Mentorship in predictive large language models (LLMs) presents both opportunities and risks of inequity if these systems are not designed with care. Mentorship quietly shapes medical careers, yet opportunities for it remain unequal. LLMs can analyze student writing and may reveal potential that exams overlook. This predictive capacity could inform fairer mentorship and direct support to students who need it most, helping build a more equitable medical workforce.
- 9 January 2026
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1) , 29
Open AccessBridging the mentorship divide: how large language models could reshape medical workforce equity
Mentorship in predictive large language models (LLMs) presents both opportunities and risks of inequity if these systems are not designed with care. Mentorship quietly shapes medical careers, yet opportunities for it remain unequal. LLMs can analyze student writing and may reveal potential that exams overlook. This predictive capacity could inform fairer mentorship and direct support to students who need it most, helping build a more equitable medical workforce.
- Open Access
- 29 December 2025
- Published by Springer Nature in AI & SOCIETY
- Vol. 41 (5) , 5429-5430
Teaching the machine to heal in Vietnam
- 29 December 2025
- Published by Springer Nature in AI & SOCIETY
- Vol. 41 (5) , 5429-5430
Open AccessTeaching the machine to heal in Vietnam
- Open Access
- 13 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Regulatory alignment in FDA expedited pathways for infectious diseases: a decadal review with predictive modeling insights
Despite infectious diseases being a significant threat to global health, there are continuing concerns that regulatory authorities do not prioritize therapeutic strategies for infectious diseases with the same urgency as those for oncological or orphan diseases. This study aims to examine the differences in the productivity of drug development and approval procedures between non-infectious and infectious diseases, and to determine the utilization patterns of acceleration programs. All molecules and biologic products approved between January 1, 2015, and December 31, 2024 (N = 464) were subject to a cross-sectional study. Drugs@FDA, the Federal Register, and ClinicalTrials.gov were used as sources of data to establish median Clinical Development Time (CDT), Regulatory Approval Time (RAT), and cumulative Regulatory Review Time (RRT). Kruskal–Wallis tests were used to compare median values (interquartile range, IQR), and chi-square tests were used for proportions. Time-to-event differences were tested using Kaplan–Meier analyses with log-rank testing, and hazard ratios (HRs) were calculated using Cox proportional hazards models. Multivariable logistic regression with interaction terms was used to model Priority Review, Fast Track, Breakthrough Therapy, and Accelerated Approval, reporting adjusted odds ratios (aOR). Of 464 approvals, 65 (14.0%) targeted infectious diseases. Median CDT was 2.76 years (IQR 1.80–4.25) versus 3.46 years (IQR 2.59–4.66; p = 0.003), and median RRT was 3.54 years (IQR 2.58–5.03) versus 4.22 years (IQR 3.24–5.73; p = 0.006) for infectious and non‑infectious drugs, respectively. Nevertheless, infectious agents were approved 58% faster (HR = 1.58; 95% CI 1.15–2.16; p = 0.0047). Infectious disease products were more likely to receive Fast Track (OR = 4.49; 95% CI 2.39–8.70) and Priority Review (OR = 10.69; 95% CI 4.57–29.50) but less likely to obtain Breakthrough Therapy (OR = 0.42; 95% CI 0.28–0.63) or Accelerated Approval (OR = 0.12; 95% CI 0.016–0.56). Infectious disease treatments outpace non-infectious disease treatments in terms of drug development and approval timelines. Nevertheless, they are less frequently utilized in pathways like Accelerated Approval, which are scientifically less applicable to acute-disease endpoints. Therefore, policy reforms should focus on addressing the underlying economic and scientific barriers to anti-infective innovation.
- 13 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessRegulatory alignment in FDA expedited pathways for infectious diseases: a decadal review with predictive modeling insights
Despite infectious diseases being a significant threat to global health, there are continuing concerns that regulatory authorities do not prioritize therapeutic strategies for infectious diseases with the same urgency as those for oncological or orphan diseases. This study aims to examine the differences in the productivity of drug development and approval procedures between non-infectious and infectious diseases, and to determine the utilization patterns of acceleration programs. All molecules and biologic products approved between January 1, 2015, and December 31, 2024 (N = 464) were subject to a cross-sectional study. Drugs@FDA, the Federal Register, and ClinicalTrials.gov were used as sources of data to establish median Clinical Development Time (CDT), Regulatory Approval Time (RAT), and cumulative Regulatory Review Time (RRT). Kruskal–Wallis tests were used to compare median values (interquartile range, IQR), and chi-square tests were used for proportions. Time-to-event differences were tested using Kaplan–Meier analyses with log-rank testing, and hazard ratios (HRs) were calculated using Cox proportional hazards models. Multivariable logistic regression with interaction terms was used to model Priority Review, Fast Track, Breakthrough Therapy, and Accelerated Approval, reporting adjusted odds ratios (aOR). Of 464 approvals, 65 (14.0%) targeted infectious diseases. Median CDT was 2.76 years (IQR 1.80–4.25) versus 3.46 years (IQR 2.59–4.66; p = 0.003), and median RRT was 3.54 years (IQR 2.58–5.03) versus 4.22 years (IQR 3.24–5.73; p = 0.006) for infectious and non‑infectious drugs, respectively. Nevertheless, infectious agents were approved 58% faster (HR = 1.58; 95% CI 1.15–2.16; p = 0.0047). Infectious disease products were more likely to receive Fast Track (OR = 4.49; 95% CI 2.39–8.70) and Priority Review (OR = 10.69; 95% CI 4.57–29.50) but less likely to obtain Breakthrough Therapy (OR = 0.42; 95% CI 0.28–0.63) or Accelerated Approval (OR = 0.12; 95% CI 0.016–0.56). Infectious disease treatments outpace non-infectious disease treatments in terms of drug development and approval timelines. Nevertheless, they are less frequently utilized in pathways like Accelerated Approval, which are scientifically less applicable to acute-disease endpoints. Therefore, policy reforms should focus on addressing the underlying economic and scientific barriers to anti-infective innovation.
- Open Access
- 9 October 2025
- Published by Springer Nature in Tropical Medicine and Health
- Vol. 53 (1) , 1-9
A step-by-step guide for conducting an umbrella review
Background: The rapid increase in published research poses challenges for healthcare professionals aiming to stay updated. While systematic reviews help synthesize findings, their abundance can overwhelm readers. Umbrella reviews address this by summarizing multiple systematic reviews, offering a comprehensive perspective on specific topics. Methods: This article offers a practical, step-by-step guide for conducting an umbrella review, aimed at researchers and clinicians alike. Results: Umbrella reviews effectively integrate data from systematic reviews, ensuring clearer evidence synthesis. Tools like Rayyan and Covidence streamline processes such as screening and data extraction. Strategies for managing overlapping studies and assessing methodological quality enhance the validity of findings. Conclusion: Umbrella reviews are invaluable for evidence-based decision-making, especially in healthcare. This guide equips researchers and clinicians with a structured approach to navigate and synthesize the growing body of systematic reviews, fostering reliable and actionable insights.
- 9 October 2025
- Published by Springer Nature in Tropical Medicine and Health
- Vol. 53 (1) , 1-9
Open AccessA step-by-step guide for conducting an umbrella review
Background: The rapid increase in published research poses challenges for healthcare professionals aiming to stay updated. While systematic reviews help synthesize findings, their abundance can overwhelm readers. Umbrella reviews address this by summarizing multiple systematic reviews, offering a comprehensive perspective on specific topics. Methods: This article offers a practical, step-by-step guide for conducting an umbrella review, aimed at researchers and clinicians alike. Results: Umbrella reviews effectively integrate data from systematic reviews, ensuring clearer evidence synthesis. Tools like Rayyan and Covidence streamline processes such as screening and data extraction. Strategies for managing overlapping studies and assessing methodological quality enhance the validity of findings. Conclusion: Umbrella reviews are invaluable for evidence-based decision-making, especially in healthcare. This guide equips researchers and clinicians with a structured approach to navigate and synthesize the growing body of systematic reviews, fostering reliable and actionable insights.
- Open Access
- 15 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 5015
Quantitative Flow Ratio-Guided vs. Angiography-Guided Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of One-Year Clinical Outcomes
Background: Quantitative Flow Ratio (QFR) is a novel, wire-free, and hyperemia-free physiological assessment for guiding Percutaneous Coronary Intervention (PCI), which may offer advantages over traditional angiography-guided PCI. This systematic review with meta-analysis compares clinical outcomes after one year in patients who underwent QFR-guided versus angiography-guided PCI. Methods: This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered on 4 November 2024 in PROSPERO (ID: CRD42024609799). A systematic search was performed across multiple databases to identify clinical trials comparing QFR-guided and angiography-guided PCI. Random-effects models were used to assess one-year outcomes of major adverse cardiovascular events (MACEs), revascularization, and rehospitalization, with heterogeneity measured using I2, H2, and Cochran’s Q statistics. Study quality was evaluated using the Cochrane Risk of Bias 2 (RoB 2) tool. Results: Compared to traditional angiography-guided PCI, QFR-guided PCI was associated with numerically lower but statistically non-significant risks of MACEs (risk difference: −0.08, 95% CI: −0.20 to 0.04), revascularization (risk difference: −0.02, 95% CI: −0.08 to 0.03), and rehospitalization (risk difference: −0.02, 95% CI: −0.08 to 0.04) over one year. Substantial heterogeneity was observed for MACEs (I2 = 84.95%, H2 = 6.64) and revascularization (I2 = 94.18%, H2 = 17.18), whereas rehospitalization exhibited low heterogeneity (I2 = 17.17%, H2 = 1.21). The risk of bias was assessed by the RoB 2 tool, which revealed low to some concern risk of bias across key domains. Conclusions: Quantitative Flow Ratio (QFR) has demonstrated comparable one-year clinical outcomes to traditional angiography for PCI guidance, with a trend toward improved results. However, the high heterogeneity among studies and the risk of bias necessitate the need for larger, high-quality trials to validate these findings.
- 15 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 5015
Open AccessQuantitative Flow Ratio-Guided vs. Angiography-Guided Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of One-Year Clinical Outcomes
Background: Quantitative Flow Ratio (QFR) is a novel, wire-free, and hyperemia-free physiological assessment for guiding Percutaneous Coronary Intervention (PCI), which may offer advantages over traditional angiography-guided PCI. This systematic review with meta-analysis compares clinical outcomes after one year in patients who underwent QFR-guided versus angiography-guided PCI. Methods: This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered on 4 November 2024 in PROSPERO (ID: CRD42024609799). A systematic search was performed across multiple databases to identify clinical trials comparing QFR-guided and angiography-guided PCI. Random-effects models were used to assess one-year outcomes of major adverse cardiovascular events (MACEs), revascularization, and rehospitalization, with heterogeneity measured using I2, H2, and Cochran’s Q statistics. Study quality was evaluated using the Cochrane Risk of Bias 2 (RoB 2) tool. Results: Compared to traditional angiography-guided PCI, QFR-guided PCI was associated with numerically lower but statistically non-significant risks of MACEs (risk difference: −0.08, 95% CI: −0.20 to 0.04), revascularization (risk difference: −0.02, 95% CI: −0.08 to 0.03), and rehospitalization (risk difference: −0.02, 95% CI: −0.08 to 0.04) over one year. Substantial heterogeneity was observed for MACEs (I2 = 84.95%, H2 = 6.64) and revascularization (I2 = 94.18%, H2 = 17.18), whereas rehospitalization exhibited low heterogeneity (I2 = 17.17%, H2 = 1.21). The risk of bias was assessed by the RoB 2 tool, which revealed low to some concern risk of bias across key domains. Conclusions: Quantitative Flow Ratio (QFR) has demonstrated comparable one-year clinical outcomes to traditional angiography for PCI guidance, with a trend toward improved results. However, the high heterogeneity among studies and the risk of bias necessitate the need for larger, high-quality trials to validate these findings.